Compare Cassava Sciences Inc (FLNA) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs QUALCOMM, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while QUALCOMM, Inc. trades at $172.55 (market cap $187.59B). The key difference: QUALCOMM, Inc. is far larger — about 3530.1× Cassava Sciences Inc's market cap, and QUALCOMM, Inc. pays a 2.07% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | QCOM | |
|---|---|---|
Market Cap | $53.14M | $187.59B |
Sector | Health | Technology |
52-Week High | $4.64 | $251.10 |
52-Week Low | $1.09 | $124.07 |
Enterprise Value | -$33.43M | $193.06B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Qualcomm (QCOM) trades at $178.08, down 3.21% today, amid a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.65 surpassing the $2.56 forecast. The company maintains strong profitability with a 54.8% gross margin and 22.31% net income margin, while diversifying into AI and automotive markets. News highlights Nvidia's entry into the PC chip market increasing competitive pressures.
The outlook is cautiously optimistic with a consensus price target of $222.53 implying 25% upside, but near-term risks include smartphone demand softness and margin pressures. Long-term growth hinges on successful expansion in AI and data centers, though competition and market volatility pose challenges to shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
